In his practice he treats cancer with fasting (fasting every other day) and by reducing solid foods; he himself can go for days without food, on sugar-cane juice only.
Original statement
انا ممكن اقعد بالايام ماكلش اصلا ماكلش يعني ماكلش يعني عصير القصب ده وخلاص انت تعرفي تعملي كده اه تعرفي بس انت مش عايزه تعملي كده انت حره برض لا خلي بالك انا السرطان عندي بعالجه بالصيام بالمناسبه صيام يوم اه يوم لا وقلل في الحاجات الصلبه
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
In his practice he treats cancer with fasting (fasting every other day) and by reducing solid foods; he himself can go for days without food, on sugar-cane juice only.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- #الدكتور_ضياء_العوضي (Open source)
- Published
- 8 March 2024
- Timestamp
- 0:00:08 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context.
- Claimed mechanism
Not stated in the excerpt.
- Claimed health effect
Treatment of cancer.
- Population concerned
Cancer patients treated by him.
- Geographic restriction by Elawady
none found
Diverging source versions
انا السرطان عندي بجه بالصيام بالمناسبه صيام يوم اه يوم لا وقلل في الحاجات الصلبه
With me, cancer - I treat it with fasting, by the way: fasting one day yes, one day no, and reduce solid foods.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- الجزء الخامس من الندوة (Open source)
- Published
- 3 March 2024
- Timestamp
- 0:00:21 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context. Same seminar passage in an earlier upload ('part five of the seminar'); 'بجه' is a transcription variant of 'بعالجه' (I treat it).
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
Alternate-day fasting and reducing solid foods are a treatment for cancer.
2. What is demonstrably correct?
Fasting during cancer therapy is an active research field. In the randomised phase 2 DIRECT trial (131 women with HER2-negative breast cancer, BMI over 18, no diabetes), a fasting-mimicking diet for a few days around each chemotherapy cycle did not improve the primary endpoint (grade III/IV toxicity) or pathological complete response, but was associated with more radiological responses (OR 3.17) and, per protocol, more near-complete pathological responses (OR 4.11) as secondary findings; adherence was poor and the senior author holds equity in the diet's manufacturer (I-INTA-08). A 2025 systematic review found intermittent fasting during chemotherapy safe and feasible under study conditions (I-INTA-10). A 2026 meta-analysis of three small studies found better tumour shrinkage on scans when patients restricted food around chemotherapy (OR 4.55, 1.64-12.58), but without effects on toxicity or quality of life and without survival data; we could not reproduce its pooled estimate (our recalculation 3.50) (I-SRC-109).
3. What is wrong or exaggerated?
These studies tested fasting only as an add-on to chemotherapy, never as a replacement. The systematic review found no demonstrated effect of intermittent fasting on treatment outcomes or toxicity (I-INTA-10). Malnutrition and muscle loss are frequent in cancer patients and worsen outcomes; European guidelines recommend regular malnutrition screening and meeting energy and protein needs (I-INTA-09). Cancer cachexia involves ongoing muscle loss that conventional nutrition cannot fully reverse (I-CAN-06), so repeated fasting and reduced solid food can be harmful. Using alternatives instead of standard treatment is associated with higher mortality (I-CHM-03, I-CHM-04). The ESMO guideline on cancer cachexia recommends nutritional screening and support for all patients on anticancer treatment and at least 25-30 kcal per kg body weight per day (I-SRC-108).
4. What remains unclear?
Whether he combined fasting with standard oncology care for his patients is not stated; no outcomes of his patients are documented. Whether short-term fasting improves survival as an adjunct is unknown.
5. Which studies support it?
None for fasting as a cancer treatment. I-INTA-08 and I-SRC-109 tested short, supervised dietary restriction only as an add-on to chemotherapy (surrogate endpoints, small studies).
6. Which studies contradict it?
I-INTA-08 (primary endpoints not improved), I-INTA-10, I-INTA-09, I-SRC-108, I-CAN-06, I-CHM-03, I-CHM-04.
7. What applies to Germany and Europe?
ESPEN guidelines (I-INTA-09) are the reference in Europe; fasting is not part of standard cancer treatment.
8. What is known about Egypt?
No Egypt-specific data; the same guideline principles apply.
9. What practical conclusion is appropriate?
Fasting is not a cancer treatment. Short fasting periods during chemotherapy should only be considered within studies or with the oncology team, in patients who are not malnourished.
Assessment details
- Rationale for certainty of evidence
No clinical study has tested fasting as a stand-alone cancer treatment; trials of short fasting or fasting-mimicking diets as an adjunct to chemotherapy are few and small, with only secondary/per-protocol signals in one phase 2 trial whose primary endpoints were null and an overall systematic review showing no demonstrated effect on outcomes. Harm from malnutrition and from replacing treatment is well documented. Certainty that fasting 'treats' cancer is therefore low, and the claim is rated mostly false rather than false because adjunct fasting is an open research question.
- Source quality
Elawady's own words in an archive machine transcript (live stream); exact wording may contain recognition errors. Spoken during a seminar (2024).
- Regional transferability
High; cancer biology and nutrition guidance are universal.
- Individual exceptions
Short, supervised fasting periods around chemotherapy are being studied in selected, well-nourished patients without diabetes (I-INTA-08).
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: In people with cancer, does alternate-day fasting and reduced solid food intake, used as treatment, improve tumour control or survival compared with standard oncology care with adequate nutrition?
Research question in detail (PICO)
- Population
- Adults with cancer
- Intervention or exposure
- Alternate-day fasting / reduced solid food as treatment (alone or with standard care)
- Comparison
- Standard cancer treatment with nutritional support
- Geographic scope
- universal biology
- Outcomes
- Overall survival
- Tumour response
- Toxicity
- Malnutrition/cachexia
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Short fasting alongside cancer treatment
Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841 Meta-analysisfull text checkednewly added2026 meta-analysis of dietary restriction during active cancer therapy (letter; full text read).
- Actual result
- Favourable radiological response OR 4.55 (1.64-12.58), 3 studies (169 patients); no significant effect on toxicity or quality of life; survival not studied.
- Methodological quality
- low (3 small studies; pooled OR not reproducible: our MH 3.50)
- Relevance
- indirect: adjunct to chemotherapy, not stand-alone treatment
- Limitations
- Malnourished patients excluded; surrogate endpoint.
Can short fasting periods help chemotherapy work?
de Groot S et al.. Nature communications 2020 · PMID 32576828 · DOI 10.1038/s41467-020-16138-3 Randomised controlled trialfull text, structured risk-of-bias assessmentDIRECT phase 2 RCT of a fasting-mimicking diet around neoadjuvant chemotherapy.
- Actual result
- Primary endpoints (toxicity, pCR) not improved; more radiological responses (OR 3.17) and per-protocol near-complete responses (OR 4.11) as secondary findings.
- Methodological quality
- moderate (RCT, poor adherence)
- Relevance
- indirect: adjunct only
- Limitations
- Secondary/per-protocol findings; senior author COI.
What speaks against the claim?
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487 Cohort studyabstract checkedNCDB cohort: complementary medicine and refusal of conventional therapy.
- Actual result
- Complementary-medicine users refused more surgery (7.0% vs 0.1%) and chemotherapy (34.1% vs 3.2%); overall death HR 2.08 (1.50-2.90), which became non-significant (HR 1.39, 0.83-2.33) after adjusting for refusal/delay, i.e. the excess risk was mediated by refusing treatment.
- Methodological quality
- low-moderate (observational)
- Relevance
- direct for replacing treatment
- Limitations
- Confounding; not about fasting specifically.
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092 Guideline / position statementabstract checkednewly addedESMO 2021 cancer cachexia guideline.
- Actual result
- Regular nutritional screening and support for all patients on anticancer therapy; at least 25-30 kcal/kg/day; protein >=1.2 g/kg/day may be needed.
- Methodological quality
- guideline
- Relevance
- direct for nutritional standard
- Limitations
- Low evidence levels for some points.
Does intermittent fasting help during chemotherapy?
Maes J et al.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025 · PMID 40970988 · DOI 10.1007/s00520-025-09907-7 Systematic reviewabstract checked2025 systematic review of intermittent fasting during chemotherapy/targeted therapy.
- Actual result
- Safe and feasible under study conditions; no demonstrated effect on outcomes or toxicity.
- Methodological quality
- moderate
- Relevance
- direct for adjunct fasting
- Limitations
- Small studies.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Fasting is not a cancer treatment; short supervised fasting as an adjunct is an open research question in well-nourished patients.
Why some studies weigh more
Guidelines and outcome data on replacing treatment weigh more than surrogate-endpoint signals from three small adjunct studies whose pooled estimate could not be reproduced.
Is a causal relationship established? Not established No trial tests fasting as stand-alone treatment; adjunct benefits are unconfirmed on survival.
Remaining uncertainty
Whether short-term fasting improves survival when added to chemotherapy; safety in malnourished patients.
Justified conclusion
Alternate-day fasting is not an evidence-based cancer treatment and conflicts with guideline nutrition standards; any fasting during therapy belongs in trials or under the oncology team.
Why do studies seem to disagree?
Apparent conflict between positive adjunct signals (I-SRC-109, I-INTA-08) and guidelines (I-SRC-108) dissolves on inspection: the trials used short, supervised fasting around chemotherapy in non-malnourished patients and measured tumour response, while guidelines address nutrition across the disease course and malnutrition risk.
Does this depend on the country?
- General biological effects
- Universal.
- Eating habits
- Ramadan-type fasting differs from alternate-day fasting during treatment.
- Origin of the food
- Not applicable.
- Contaminants
- Not applicable.
- National production conditions
- Not applicable.
- Legal rules
- Not applicable.
- Actual monitoring data
- No Egyptian data.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Recompute per-study ORs from Table 1, Mantel-Haenszel pooled OR, CI symmetry – Per-study ORs 3.75, 2.89, 6.18 (continuity-corrected); MH OR 3.50 vs reported fixed 4.80 and random 4.55; reported CIs log-symmetric. Pooled estimate exceeds two of three study ORs and could not be reproduced. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Survival/tumour control with fasting as cancer treatment
- Starting level
- high (randomised trials)
- Reasons for downgrading
- indirectness: only adjunct studies with surrogate endpoints
- imprecision: very few small studies
- risk of bias: open-label, poor adherence
- Result
- very low
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ESMO: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines (2021) · Original publication
Regular nutritional screening and support for patients on anticancer treatment [V, B]; at least 25-30 kcal/kg/day [V, B]; escalate nutritional interventions when intake is inadequate during anticancer therapy [II, A]. - ESPEN: ESPEN practical guideline: Clinical Nutrition in cancer (2021) · Original publication
Abstract only: 43 recommendations on nutritional and metabolic management of cancer patients, preceded by diagnostics of nutritional status (specific statements not read).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | ("short-term fasting" OR "fasting mimicking" OR "intermittent fasting" OR "alternate day fasting") AND cancer AND (randomized OR randomised) AND (chemotherapy OR survival OR response) AND PUB_YEAR:[2020 TO 2026] | supporting evidence | 1828 | |
| Europe PMC | 26 October 2026 | (fasting OR "caloric restriction") AND cancer patients AND (meta-analysis OR "systematic review") AND (survival OR toxicity OR "quality of life") AND PUB_YEAR:[2022 TO 2026] | both directions | 13348 | |
| PubMed | 26 October 2026 | ESPEN practical guideline clinical nutrition in cancer | guidelines | 40 | |
| PubMed | 26 October 2026 | cancer cachexia ESMO clinical practice guideline 2021 | guidelines | 1 | |
| PubMed | 26 October 2026 | (alternative medicine OR complementary medicine OR "refusal of conventional") AND cancer AND survival AND (cohort OR "National Cancer Database") | contradicting evidence | 2446 |
Open questions
Survival effect of supervised fasting as an adjunct; reproduction of the pooled OR.
How deeply was this checked?
8 linked studies: 2 checked in full text (1 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly false (low)
New 2026 meta-analysis adds a weak, partly irreproducible adjunct signal and the ESMO guideline confirms nutritional standards; verdict and low certainty unchanged.
New sources: I-SRC-108 I-SRC-109
In plain language
Dr. Elawady said he treats cancer with fasting every other day and by eating less solid food. Some small studies are testing short fasting periods alongside chemotherapy, and one trial in breast cancer showed better tumour response. But no study shows that fasting alone treats cancer, and an overview of nine studies found no proven effect on treatment results. Many cancer patients lose weight and muscle, which makes outcomes worse, so doctors aim to make sure they eat enough.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (7)
-
Does intermittent fasting help during chemotherapy?
Maes J et al.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025 · PMID 40970988 · DOI 10.1007/s00520-025-09907-7Systematic reviewindependent cross-checkabstract checked★ key studyNine small studies found fasting feasible and safe under supervision but showed no proven effect on treatment results or side effects.
No demonstrated effect on treatment outcomes.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Intermittent fasting during cancer therapy
- How was the study done?
Systematic review
- How many people, animals or samples were studied?
9 studies, 354 patients
- What was actually found?
Safe and feasible; no demonstrated effect on outcomes
- How large was the observed effect?
Not pooled
- What do the results mean in everyday life?
Fasting is not a proven cancer treatment
- What are the study's limitations?
Few small studies
- What does it say about Elawady's specific claim?
Contradicts 'treating cancer with fasting'
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Effects of fasting without standard treatment (not studied)
-
What should cancer patients eat?
Arends J et al.. Clinical nutrition (Edinburgh, Scotland) 2017 · PMID 27637832 · DOI 10.1016/j.clnu.2016.07.015Guideline / position statementindependent cross-checkabstract checked★ key studyEuropean guidelines say cancer patients should be screened for malnutrition and should get enough energy and protein.
Guideline aims to meet energy needs and prevent malnutrition in cancer patients.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Nutrition in cancer
- How was the study done?
Clinical guideline (GRADE)
- How many people, animals or samples were studied?
Adult cancer patients
- What was actually found?
Malnutrition worsens outcomes; energy needs should be met
- How large was the observed effect?
Not applicable
- What do the results mean in everyday life?
Deliberately eating less is risky for many cancer patients
- What are the study's limitations?
Abstract only
- What does it say about Elawady's specific claim?
Contradicts fasting as a general cancer treatment
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Effects of short supervised fasting
-
Cancer wasting is caused by the cancer itself
Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7Guideline / position statementindependent cross-checkabstract checkedExperts define cachexia as muscle loss driven by the tumour's effects on metabolism and appetite, not fully reversible by food.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Define cachexia.
- How was the study done?
Delphi consensus.
- How many people, animals or samples were studied?
Experts.
- What was actually found?
Definition.
- What do the results mean in everyday life?
Weight loss in cancer needs medical attention.
- What are the study's limitations?
Consensus.
- What does it say about Elawady's specific claim?
Contradicts 'not dying of cancer'.
- Do the results apply to Germany and Europe?
High.
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145Cohort studyindependent cross-checkabstract checked★ key studyRisk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare AM-only vs conventional treatment.
- How was the study done?
Matched registry cohort.
- How many people, animals or samples were studied?
840 matched patients.
- What was actually found?
HR 2.50 for death.
- How large was the observed effect?
HR 5.68 breast cancer.
- What do the results mean in everyday life?
Replacing cancer treatment with alternatives is dangerous.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusing therapy.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Effects of complementary approaches used alongside treatment.
-
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487Cohort studyindependent cross-checkabstract checked★ key studyUsers of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Study CM and survival.
- How was the study done?
Registry cohort.
- How many people, animals or samples were studied?
258 vs 1,032.
- What was actually found?
HR 2.08; explained by refusal.
- How large was the observed effect?
5-y OS 82.2% vs 86.6%.
- What do the results mean in everyday life?
Diet or other approaches alongside treatment are not the problem; replacing treatment is.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusal advice.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Causal effect of any single CM.
-
Can short fasting periods help chemotherapy work?
de Groot S et al.. Nature communications 2020 · PMID 32576828 · DOI 10.1038/s41467-020-16138-3Randomised controlled trialindependent cross-checkfull text, structured risk-of-bias assessment★ key studyIn 131 women with breast cancer, a fasting-mimicking diet around chemotherapy did not reduce severe side effects or increase complete tumour disappearance (the main outcomes); tumour shrinkage on imaging was more frequent, but this was a secondary result.
Fasting-mimicking diet showed better tumour response as an adjunct to chemotherapy, not as stand-alone treatment.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Fasting-mimicking diet with chemotherapy
- How was the study done?
Randomised phase 2 trial
- How many people, animals or samples were studied?
131 women, HER2-negative breast cancer
- What was actually found?
More tumour responses with FMD; no toxicity difference
- How large was the observed effect?
pCR 10.8% vs 12.7% (no difference); radiological response OR 3.17 (1.06-9.45); pathological response OR 4.11 (per-protocol)
- What do the results mean in everyday life?
Fasting may become a supportive tool during chemotherapy, under supervision
- What are the study's limitations?
Phase 2; main outcomes not improved; benefit only in secondary and per-protocol analyses; poor adherence; lead author holds equity in the diet's manufacturer
- What does it say about Elawady's specific claim?
Supports research on fasting as an add-on, not fasting instead of treatment
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
That fasting alone treats cancer
-
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092Guideline / position statementindependent cross-checkabstract checkedCancer patients on treatment should be screened for malnutrition and get at least 25-30 kcal per kg body weight per day.
Guideline requires at least 25-30 kcal/kg/day and adequate protein during cancer therapy.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide cachexia care
- How was the study done?
Guideline
- How many people, animals or samples were studied?
not applicable
- What was actually found?
Screen and feed adequately; escalate nutrition when intake is low
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Cancer patients need enough food, not fasting regimes
- What are the study's limitations?
Low evidence levels for some points
- What does it say about Elawady's specific claim?
Contradicts fasting as treatment
- Do the results apply to Germany and Europe?
High
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Short fasting alongside cancer treatment
Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841Meta-analysisindependent cross-checkfull text checked★ key studyIn three small studies, patients who restricted food during chemotherapy had better tumour shrinkage on scans; survival was not studied.
Adjunct restriction during chemotherapy associated with better radiological response in 3 small studies; not a replacement for treatment.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Pool studies of dietary restriction during cancer therapy
- How was the study done?
Systematic review and meta-analysis
- How many people, animals or samples were studied?
3 studies (169 patients) for response
- What was actually found?
Better radiological response; no clear change in toxicity or quality of life
- How large was the observed effect?
OR 4.55 (1.64-12.58), not reproducible (our MH 3.50)
- What do the results mean in everyday life?
Fasting is being studied only as an add-on to treatment
- What are the study's limitations?
Very small evidence base; reporting problems
- What does it say about Elawady's specific claim?
Does not support fasting instead of treatment
- Do the results apply to Germany and Europe?
Research setting
- What can explicitly not be concluded from this study?
Whether fasting prolongs life or replaces treatment
No study in this group is marked as key.
Regional context
Germany / EU
ESPEN guidelines (I-INTA-09) are the reference in Europe; fasting is not part of standard cancer treatment.
Egypt
No Egypt-specific data; the same guideline principles apply.
What applies in my country?
General scientific assessment
Mostly false Fasting may become a supportive tool during chemotherapy, but it is not a treatment for cancer and can be harmful when it causes malnutrition or replaces therapy.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Impact of intermittent fasting on patients with cancer undergoing chemotherapy and/or targeted therapies: a systematic review of the literature.. Maes J et al.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025 · PMID 40970988 · DOI 10.1007/s00520-025-09907-7
- ESPEN guidelines on nutrition in cancer patients.. Arends J et al.. Clinical nutrition (Edinburgh, Scotland) 2017 · PMID 27637832 · DOI 10.1016/j.clnu.2016.07.015
- Definition and classification of cancer cachexia: an international consensus.. Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
- Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.. de Groot S et al.. Nature communications 2020 · PMID 32576828 · DOI 10.1038/s41467-020-16138-3
- Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆.. Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092
- Dietary restriction during active cancer therapy is associated with improved treatment response: a systematic review and meta-analysis.. Agrawal K et al.. Cancer Biol Med 2026 · PMID 42444194 · DOI 10.20892/j.issn.2095-3941.2025.0841